🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 7 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/03/2025 52,32 52,75 49,95 51,80 -2,02% 5,35% 1.076.900
03/03/2025 55,26 55,60 52,52 52,87 -4,33% 5,57% 1.001.000
28/02/2025 45,45 55,41 44,31 55,26 +9,27% 24,42% 1.921.400
27/02/2025 50,79 52,60 50,47 50,57 -0,77% 4,19% 947.300
26/02/2025 50,84 51,75 49,78 50,96 +1,19% 3,87% 481.500
25/02/2025 50,02 50,58 48,54 50,36 +0,68% 4,08% 639.200
24/02/2025 50,47 51,00 49,53 50,02 -1,32% 2,91% 524.300
21/02/2025 50,73 51,18 50,03 50,69 +0,62% 2,26% 423.000
20/02/2025 50,33 50,67 49,57 50,38 -0,09% 2,18% 497.100
19/02/2025 50,18 51,46 49,68 50,43 +1,99% 3,55% 639.000
18/02/2025 52,50 52,95 49,39 49,44 -4,59% 6,78% 786.400
14/02/2025 50,06 52,00 49,73 51,82 +4,33% 4,53% 795.600
13/02/2025 49,33 49,98 47,76 49,67 +1,51% 4,50% 526.800
12/02/2025 47,64 48,99 47,26 48,93 +0,61% 3,63% 515.200
11/02/2025 49,32 49,65 47,73 48,64 -2,38% 3,89% 666.300
10/02/2025 49,67 50,33 48,84 49,82 +0,71% 3,00% 889.500
07/02/2025 49,82 50,84 49,17 49,47 -0,64% 3,36% 425.400
06/02/2025 49,95 50,74 49,07 49,79 -0,40% 3,34% 1.288.400
05/02/2025 49,51 50,62 49,20 49,99 +1,24% 2,87% 911.700
04/02/2025 50,01 51,31 48,60 49,38 -1,26% 5,41% 1.216.700
03/02/2025 45,86 50,45 45,73 50,01 +9,00% 10,29% 1.413.200
31/01/2025 45,95 47,54 45,52 45,88 -0,59% 4,39% 1.017.100
30/01/2025 45,67 46,52 45,20 46,15 +2,06% 2,89% 434.700
29/01/2025 45,08 46,42 44,82 45,22 +0,07% 3,55% 408.800
28/01/2025 46,23 46,23 45,04 45,19 -1,91% 2,57% 390.000
27/01/2025 46,00 47,29 45,05 46,07 -0,82% 4,87% 549.500
24/01/2025 46,00 47,09 44,44 46,45 +0,58% 5,76% 545.800
23/01/2025 44,86 46,60 44,30 46,18 +2,44% 5,13% 898.700
22/01/2025 45,31 45,40 43,94 45,08 -0,38% 3,21% 600.200
21/01/2025 44,27 45,28 42,97 45,25 +3,22% 5,22% 784.600